Related Experiment Video
Updated: Jan 9, 2026
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Programmable nanomotor system responsively and chemotactically captures tumor associated antigens for enhanced in
Panpan Song1,2,3, Xiaoqing Han2, Yanjing Wang1,2,3
1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120, China.
Abstract:
In situ cancer vaccines that utilize the body's own tumor-associated antigens (TAAs) to induce tumor-specific adaptive immune responses are emerging as a promising strategy in cancer therapy. However, the rapid clearance of TAAs due to innate immune system hinders the development of effective antitumor immunity. To address this challenge, we developed a nanomotor system (DDMSN@MOMVPF) as an in situ cancer vaccine capable of chemotactically capturing TAAs, significantly inhibiting the rapid clearance of TAAs and enhancing cancer immunotherapy. In response to acid tumor microenvironment, DDMSN@MOMVPF exfoliated folate acid-attached, mitoxantrone-embedded bacterial outer membrane vesicle (OMV) fragments, which could be specifically taken up by tumor cells to induce immunogenic cell death (ICD) and release DNA-associated TAAs. Subsequently, the exposed DNase on DDMSN@MOMVPF detected DNA gradient and propelled nanoparticles chemotactically capturing TAAs. In vivo results indicated that DDMSN@MOMVPF suppressed both primary and distant tumors and elicited immune memory effects to prevent tumor recurrence.
Insights
This study introduces a novel nanomotor system for in situ cancer vaccines. This system captures tumor-associated antigens (TAAs), enhancing cancer immunotherapy and preventing tumor recurrence.
Area of Science:
- Biomedical Engineering
- Immunology
- Nanotechnology
Background:
- In situ cancer vaccines using tumor-associated antigens (TAAs) show promise for cancer therapy.
- Rapid clearance of TAAs by the innate immune system limits the efficacy of current cancer vaccines.
- Developing strategies to prolong TAA presence is crucial for effective antitumor immunity.
Purpose of the Study:
- To develop a nanomotor system (DMSN@MOMVPF) for in situ cancer vaccination.
- To enhance cancer immunotherapy by overcoming rapid TAA clearance.
- To improve the induction of tumor-specific adaptive immune responses.
Main Methods:
- Engineered a nanomotor system (DMSN@MOMVPF) that responds to acidic tumor microenvironments.
- Utilized folate-attached, mitoxantrone-embedded bacterial outer membrane vesicle (OMV) fragments for tumor cell uptake and induction of immunogenic cell death (ICD).
- Incorporated DNase for chemotactic propulsion to capture TAAs based on DNA gradients.
Main Results:
- The nanomotor system effectively captured TAAs, inhibiting their rapid clearance.
- Demonstrated suppression of both primary and distant tumors in vivo.
- Elicited significant immune memory effects, preventing tumor recurrence.
Conclusions:
- The developed nanomotor system serves as an effective in situ cancer vaccine.
- This approach enhances cancer immunotherapy by prolonging TAA availability and stimulating immune responses.
- The system holds potential for preventing tumor recurrence through induced immune memory.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...